Theravance Biopharma TBPH EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
Based on trailing twelve months.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's EBITDA margin?
- Theravance Biopharma (TBPH) reported EBITDA margin of 2.7% in Q1 2026.
- How has Theravance Biopharma's EBITDA margin changed year-over-year?
- Theravance Biopharma's EBITDA margin increased by 103.6% year-over-year, from -74.3% to 2.7%.
- What is the long-term trend for Theravance Biopharma's EBITDA margin?
- Over 4 years (2021 to 2025), Theravance Biopharma's EBITDA margin has grown at a -74.8% compound annual growth rate (CAGR), from -457.4% to -1.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.